Study finds potential new drug target for lung cancer

A new study by University of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer.

Published in the¬†Journal of Clinical Investigation, the study collected metabolic data directly from more than 120 human lung cancer patients.¬†UK’s Center for Environmental and Systems Biochemistry (CESB) researchers Teresa Fan, Andrew Lane, and Richard Higashi led the study, with work done at both UK and the University of Louisville.